

The FDA just asked the public to help design an AI clinical trial pilot program, with selections planned for August 2026. This isn't a vague exploration; it's a live procurement process that could set the rules for AI in drug development for years to come.
Imagine the most powerful drug regulator on Earth posting the equivalent of a Reddit "help me figure this out" thread. That's basically what happened last month.
The FDA published a formal Request for Information (an RFI, in government-speak) asking the public how it should build a pilot program for AI-enabled optimization of early-phase clinical trials. Comments are due May 29, 2026. And the agency plans to pick its pilot participants by August.
This isn't a press release about "exploring possibilities." It's a procurement process with a timeline. The FDA is building something, and it wants your input on the blueprints.
To appreciate how big this is, you need to see the arc. The FDA has been circling AI in drug development for years, like someone hovering over the "Buy Now" button.
In 2023, CDER (the arm of FDA that oversees drug approvals) published a discussion paper about AI and machine learning in drug development. In early 2024, the agency released a cross-center collaboration paper showing that CDER, CBER (biologics), and CDRH (devices) were all trying to get on the same page. By January 2025, the agency dropped a full draft guidance on using AI to support regulatory decisions for drugs and biologics.
Then came the "Guiding Principles of Good AI Practice in Drug Development," co-developed with the European Medicines Agency. Ten principles. Non-binding, but normative.
So the progression is clear: discussion paper, workshops, collaboration paper, draft guidance, guiding principles, and now... a live pilot. The FDA went from "we're thinking about it" to "tell us how to do it" in about three years.
Early-phase trials (Phase 1 and early Phase 2) are where drugs meet humans for the first time. They're small, high-stakes, and surprisingly clunky. The core questions sound simple: What dose is safe? What dose actually works? Should we keep going or kill this program?
In practice, those questions are brutally hard to answer. Traditional dose-finding designs, like the classic 3+3 method (test three patients, then three more), are statistically inefficient. They often the right dose. Meanwhile, the FDA's own Project Optimus initiative now pushes sponsors to test a of doses rather than just finding the maximum tolerated one. That means bigger studies, more data, and more complex designs.

The FDA just proved it can watch clinical trial data in real time, not months after the fact. AstraZeneca and Amgen are the first guinea pigs in an initiative that could cut drug development timelines by up to 40%.


Join thousands of biotech professionals who start their day with our free, daily briefing.
Think of it like this: the old approach was trying to find the spiciest salsa you could handle. The new approach asks you to taste five salsas and rank them by flavor, heat, and how your stomach feels the next morning. It's a better system, but it's a lot more work.
AI could help by crunching real-time safety data, optimizing dose-escalation decisions, flagging safety signals earlier, and running thousands of trial simulations before a single patient enrolls. The FDA's RFI specifically calls out dose selection, adaptive trial designs, safety monitoring, and early go/no-go decisions as areas where AI could make a difference.
The RFI (Docket FDA-2026-N-4390, for the curious) is open to literally anyone. Pharma companies, biotech startups, AI vendors, academic researchers, patient groups, CROs: all welcome. There's no restriction to U.S. entities mentioned in the notice.
The FDA wants input on five big buckets:
That last one is especially interesting. The FDA is explicitly asking how to judge whether an AI tool is fair, transparent, explainable, and safe enough for regulated clinical trials. That's not a throwaway question; it's the whole ballgame.
The timeline here is aggressive by government standards. Comments close May 29. Final selection criteria go out in July. Pilot selections happen in August. That's roughly 90 days from "tell us what you think" to "you're in or you're out."
For AI-forward sponsors and tech companies, this is a first-mover opportunity. Getting into the pilot means direct collaboration with FDA reviewers, a chance to shape evaluation metrics, and (perhaps most valuable) early insight into how the agency will eventually regulate AI in clinical trials for everyone else.
For the broader industry, the pilot will likely set precedents that ripple through drug development for years. The metrics the FDA uses to judge "good AI" in this pilot will become the de facto standard.
The RFI doesn't name specific companies, but you can sketch the profile of ideal candidates. They'd be sponsors running Phase 1 or early Phase 2 trials under CDER, CBER, or the Oncology Center of Excellence. They'd use AI for something specific and consequential: not just automating paperwork, but influencing dose decisions, safety calls, or trial design.
The FDA has already run a real-time clinical trials proof-of-concept with AstraZeneca and Amgen, using a company called Paradigm Health for the data infrastructure. That gives you a sense of the type of collaboration the agency is comfortable with.
AI-native trial design platforms, model-based dose-optimization companies, and real-time data streaming startups all fit the bill. But the FDA's emphasis on explainability and governance means that black-box algorithms, no matter how impressive, will face headwinds. If you can't explain how your model makes a recommendation, you probably can't participate.
This pilot is one piece of a larger FDA digital health push. The agency's Digital Health Center of Excellence launched the TEMPO pilot in early 2026, focused on AI-enabled digital health devices. CDER's Center for Clinical Trial Innovation (C3TI) offers structured engagement on innovative trial designs. The Drug Development Tools program can qualify AI-based tools similarly to biomarkers.
All of these programs share a common philosophy: risk-based, lifecycle-managed, transparent AI that can be validated, monitored, and explained. The FDA isn't anti-AI. It's anti-mystery.
The RFI deadline is May 29, 2026. If your organization uses AI in early-phase trials, or plans to, this is your chance to help write the rules before they're written for you.
Astellas Pharma's biggest drug generates over 40% of its revenue and loses U.S. patent protection in 2027. The company just laid out an aggressive plan to buy, partner, and cut its way through the storm, and it's adding serious heat to an already competitive biotech M&A market.